82626-01-5

Basic information

• Product Name: ALPIDEM
• Synonyms: ALPIDEM;6-Chloro-2-(p-chlorophenyl)-N,N-dipropylimidazo(1,2-a)pyridine-3-aceta mide;6-Chloro-2-(4-chlorophenyl)-N,N-dipropyl-imidazo[1,2-α]pyridine-3-acetamide;SL 80.0342-00;6-Chloro-2-(4-chlorophenyl)-N,N-dipropyl-imidazo[1,2-a]pyridine-3-acetamide;6-Chloro-2-(4-chlorophenyl)-N，N-dipmpylimidazol[1，2-α]pyridine-3-acetamide;inanxyl;SL-80．0342
• CAS NO: 82626-01-5
• Molecular Formula: C21H23Cl2N3O
• Molecular Weight: 404.33
• Product Categories: Aromatics Compounds;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 82626-01-5.mol
• Article Data: 0

Chemical Properties

• Melting Point: 136-138°C
• Appearance: white to tan/
• Density: 1.24 g/cm³
• Refractive Index: 1.606
• Storage Temp.: Refrigerator
• Solubility: DMSO: ≥10mg/mL
• PKA: 4.74±0.50(Predicted)
• CAS DataBase Reference: ALPIDEM(CAS DataBase Reference)
• NIST Chemistry Reference: ALPIDEM(82626-01-5)
• EPA Substance Registry System: ALPIDEM(82626-01-5)

Safety Data

• Hazardous Substances Data: 82626-01-5(Hazardous Substances Data)

Usage

Description

ALPIDEM, also known as Ananxyl, is an imidazopyridine antianxiety agent with anticonvulsant properties. It is the first non-benzodiazepine anxiolytic to show selectivity for the omega-1 modulatory site of the GABA receptors. ALPIDEM is reported to be superior to buspirone and similar to benzodiazepines, but with significantly better tolerance and lower abuse potential. It is a white to off-white solid and is marketed under the brand name Ananxyl.

Uses

Used in Pharmaceutical Industry:
ALPIDEM is used as a peripheral benzodiazepine GABAA receptor ligand for its anxiolytic properties. It is particularly effective in treating anxiety disorders and is considered a new anxiolytic option.
Used in Mental Health Applications:
ALPIDEM is used as an anxiolytic agent for the treatment of anxiety disorders, providing relief from symptoms and improving the quality of life for patients. Its selectivity for the omega-1 modulatory site of the GABA receptors allows for better tolerance and lower abuse potential compared to traditional benzodiazepines.

Biochem/physiol Actions

Alpidem is a potent antagonist of peripheral benzodiazepine receptor (PBR) that is located on the outer mitochondrial membrane and interacts with the mitochondrial permeability transition (MPT) pore. Alpidem is an anxiolytic drug from the imidazopyridine family. Alpidem acts selectively on the α3 receptor subtype and to a lesser extent at the α1 subtype (Kd of 0.33nM and 1.67nM respectively), of the benzodiazepine receptor.

Clinical claims and research

Alpidem is an imidazopyridine partial agonist that also shows relative selectivity for the type I benzodiazepine receptor. Studies have shown an anxiolytic effect comparable with the classic benzodiazepines, but with an improved adverse effect profile (Pancheri et al. 1993). It has also been compared with buspirone in patients with generalized anxiety disorder and shown to be more rapidly effective and again to have a more favorable adverse effect profile (Legris et al. 1993). Longer-term studies with alpidem have shown that tolerance does not occur, and no significant problems of withdrawal on discontinuation were found (Chevalier et al. 1993). Alpidem was licensed in France for the treatment of anxiety but has now been suspended because of recent reports of alpidem-induced hepatic dysfunction. The reason for this is unclear, but it may be a reflection of the fact that alpidem also binds to peripheral benzodiazepine receptors, which are present in high density in the liver.

InChI:InChI=1/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3